Clarithromycin 250 mg b. i. d. for 5 or 10 days in the treatment of adult patients with purulent bronchitis
Tóm tắt
This Phase III, double-blind, randomized, multicenter study compared the safety and efficacy of clarithromycin, 250 mg b. i. d administered for either 5 or 10 days, in the treatment of 221 adult patients with purulent bronchitis. Clinical evaluations were performed pre-treatment, during treatment, post-treatment, and at a follow-up visit. Both regimens were well tolerated and effective. No significant differences were observed between patients treated for 5 days and those treated for 10 days in post-treatment, clinical success (98%, 83/85; 99%, 73/74, respectively), or bacterial eradication (100%, 37/37; 94%, 33/35) rates, or in the number of patients reporting drug-related adverse events (16%, 18/112; 24%, 26/109, respectively). Clarithromycin administered for 5 days was at least as safe and as effective as a 10-day regimen in the treatment of purulent bronchitis.
Tài liệu tham khảo
Aderson, G. Clarithromycin in the treatment of community-acquired lower respiratory tract infections. J. Hospital Infection 19 (Suppl A) (1991) 21–27.
Aldons, P. M. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J. Antimicrob. Chemother. 27 (Suppl A) (1991) 101–108.
Vogel, F. Efficacy and tolerability of clarithromycin in the short-course treatment of acute respiratory tract infections. Drug Invest. 3 (1991) 205–209.
O'Neill, S. J., Millar, E. D., Coles, S. J., Bachand, R. T. Safety and efficacy of clarithromycin in the treatment of acute mild to moderate respiratory tract infections. Irish Med. J. 84 (1991) 33–35.
COSTART Coding symbols for thesaurus of adverse reaction terms. 3rd edition. Rockville MD. Dept. of Health and Human Services, FDA, (1990).
INSTAT Statistical Package Version 5.31; Users Manual (1990). University of Reading, England.
Aldons, P. M. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J. Antimicrob. Chemother. 27 (Suppl A) (1991) 101–108.
Bachand, R. T. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 27 (Suppl A) (1991) 91–100.
Fraschini, F. Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbation of chronic bronchitis. J. Int. Med. Res. 18 (1990) 171–176.
Guay, D. R. P., Craft, J. C. Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis. J. Internal Medicine 231 (1992) 295–301.
Anderson, G. Clarithromycin in the treatment of community-acquired lower respiratory tract infections. J. Hospital Infection 19 (Suppl A) (1991) 21–27.
Bachand, R. T. A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis. J. Antimicrob. Chemother. 27 (Suppl A) (1991) 75–82.
Karma, P., Pukander, J., Penttila, M., Ylikoski, J., Savolainen, S., Olen, L., Melen, I., Loth, S. The comparative efficacy and safety of clarithromycin and amoxicillin in the treatment of outpatients with acute maxillary sinusitis. J. Antimicrob. Chemother. 27 (Suppl A) (1991) 83–90.
Stein, G. E., Christensen, S., Munnaw, N. Comparative study of clarithromycin and penicillin V in the treatment of streptococcal pharyngitis. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 949–953.
Hardy, D. J., Guay, D. R. P., Jones, R. N. Clarithromycin, a unique macrolide. Diagn. Microbiol. Infect. Dis. 15 (1992) 39–53.
Wood, M. J. More macrolides: some may be improvements on erythromycin. Br. Med. J. 303 (1991) 594–595.